Table 1 Current Indications for CEM

High-risk screening (not an FDA approved indication but under investigation)

Supplementation to screening mammography in heterogeneously dense and extremely dense breast parenchyma in accordance with local state regulations, usually in the setting of dense breast clinic

Further assessment of inconclusive findings on diagnostic workup

Assessment of palpable abnormality with negative prior workup

Staging of known breast cancer, particularly in patients with contraindications to MRI

Assessment of response to chemotherapy, especially in patients with contraindications to MRI